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Transthyretin is the carrier protein of thyroxine and retinol in plasma and cerebrospinal ﬂuid and
has been described also as a neuroprotective molecule. 14-3-3 Proteins are very important in many
cellular processes, being their absence related with deﬁcits in memory and learning. The analysis of
the relationship between these two proteins is the main objective of this work. We found that hip-
pocampi of young TTR null mice presented lower levels of 14-3-3f protein, but no changes in gene
expression when compared to TTR wild type littermates were noted. Cellular studies ascribed this
ﬁnding to increased degradation of 14-3-3f in lysosomes in the absence of TTR, increasing
autophagy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Transthyretin (TTR) is a 55 kDa homotetrameric protein mainly
synthetized in liver and choroid plexus [1,2], being up-regulated by
sex hormones [3,4]. It is the carrier protein of thyroxine (T4) [5]
and retinol through the binding protein (RBP) in plasma and cere-
brospinal ﬂuid (CSF) [6]. Besides its effects on the transport of ret-
inol and T4, TTR has been described as associated with high density
lipoproteins [7]. It has also been shown to have neuroprotective
properties described in several contexts. Studies in TTR null mice
revealed that absence of TTR reduces signs of depressive- like
behavior [8], increases the levels of neuropeptide Y [9] and delays
nerve regeneration in nerve injury conditions [10]. TTR has also a
protective role in Alzheimer’s disease [11], and is able to modulate
brain Ab levels [12]. In cerebral ischemia, CSF TTR inﬂuences the
survival of endangered neurons [13].
Aiming to dissect differential expression/post-translational
modiﬁcations between wild type an TTR null mice, two-Dimen-
sional (2D) electrophoresis studies were initially performed;
among other differences, the hippocampus of TTR null mice dis-
played lower levels of 14-3-3f protein when compared to TTR wild
type littermate mice, which prompted further studies to conﬁrm
this ﬁnding.
14-3-3 proteins are a family of highly conserved acidic proteins
representing 1% of the total amount of brain protein [14]. There areseven known isoforms of 14-3-3 proteins in mammalian cells (b, g,
c, s, f, e, r) [15], each of them encoded by different genes; just r
and s/h are non-neuronally expressed [16].
14-3-3 proteins can interact with more than 400 molecules
through phospho-serine/phospho-threonine residues [17], a key
regulatory mechanism in cell biology. These proteins had emerged
as essential factors in many biological processes such as signal
transduction, cell-cycle regulation, cell survival, cellular trafﬁcking,
cytoskeletal organization, protein synthesis, redox-regulation, pro-
tein folding with consequences in neurodegenerative and neurode-
velopmental disorders [18–21].
Several studies revealed that the absence of 14-3-3f induces a
deﬁcit in memory and learning [22–24]; on the other hand, young
TTR null mice present spatial memory impairment [25]. Thus, it is
important to analyze the relationship between these two proteins
in the central nervous system (CNS), particularly in the hippocam-
pus. In the present report we describe the regulation of 14-3-3f
protein levels by TTR, studied both in mice and in cell culture
experiments.
2. Materials and methods
2.1. Animals
Mice were handled according to European Union and National
rules. Three, 6 and 12-month-old TTR wild type (+/+) and TTR
knockout (/) [26], in a 129/svJ background were obtained from
the littermate offspring of heterozygous breeding pairs. The
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with regular rodent’s chow and tap water ad libitum. Genotypes
were determined from tail extracted genomic DNA, using primers
for the detection of exon 2 of TTR (which is disrupted in TTR/
by insertion of neomycin resistance gene) as previously described
[26]. Animals were euthanized under anesthesia. Half brain was
ﬁxed in 4% neutral buffered formalin, embedded in parafﬁn and
the remaining half portion was dissected and frozen at 80 C.
All efforts were made to minimize pain and distress; all animal
experiments were carried out in accordance with the European
Communities Council Directive.
2.2. Cell culture
The AF5 rat mesencephalic cell line (kindly given by Dr. William
Freed, Baltimore) was grown in DMEM (Dulbecco’s modiﬁed Eagle’s
medium) high glucose/F12 with 10% fetal bovine serum (FBS) at
37 C in a humidiﬁed incubator of 5%CO2/95%air. At 90% conﬂuence,
FBS was withdrawn and medium supplemented with 10% of TTR+/+
or TTR/ mouse serum during 18 h; in some experiments MG132
(Calbiochem) proteasome inhibitor and chloroquine (Sigma) lyso-
some inhibitorwere addedduring 30 min. before serumwithdrawn.
Primary cultures of mouse hippocampal neurons were prepared
from the hippocampus of E18–E19 TTR/ mice embryos. The hip-
pocampi were treated with trypsin (0.5 mg/ml, 15 min at 37 C) in
Ca2+ and Mg2+ HBSS (Hank’s Balanced Salt Solution) free. The hip-
pocampi were then washed in HBSS supplemented with 10% FBS.
After centrifugation at 140_gav, for 1 min, cells were mechanically
dissociated in HBSS. Hippocampal cultures were maintained in ser-
um-free Neurobasal medium supplemented with B27, glutamate
(25 mM), glutamine (0.5 mM) and gentamicin (0.12 mg/ml). Cells
were kept at 37 C in a humidiﬁed incubator of 5% CO2/95% air,
for 7–8 days, the time required for maturation of hippocampal
neurons [27]. All culture media used were from GIBCO.
2.3. Two-Dimensional electrophoresis studies
Cold acetone precipitates from hippocampal extracts of TTR+/+
and TTR/ littermate mice were prepared and treated with 2D
Clean Up Kit (GE Healthcare). Protein pellets were dissolved in
7 M urea, 2 M thiourea and 0.5% Pharmalyte pH 3–10 (GE Health-
care) containing buffer. Protein concentration was determined
using the Bradford protein assay (Bio Rad). Approximately 100 lg
of protein were applied to Immobiline DryStrips (18 cm, pH 3–10
NL (non-linear), GE Healthcare), isoelectric focusing performed
on an IPGphor system (GE Healthcare). The proteins were then
subsequently separated on the second dimension in a SDS–PAGE
gel under reducing conditions.
The ﬁxed gels were then silver stained. Digital images of the 2D
PAGEmapswere acquired using a gel scanner. PDQuest Image Anal-
ysis software was used to identify differentially regulated proteins;
the procedurewasperformed twice in duplicated samples. Differen-
tial spots were excised and MALDI mass spectroscopic analysis was
performed on a PerSeptive Voyager mass spectrometer.
2.4. Immunohistochemistry
Brain samples were ﬁxed in 4% neutral buffered formalin and
embedded in parafﬁn. For immunohistochemistry, brainswere seri-
ally sectioned into 4 lm thick sections in a microtome (Microm
HM335E). Sections were deparafﬁnized in xylol and dehydrated in
a descendent alcohol series. Endogenous peroxidase activity was
inhibited with 3% hydrogen peroxide in methanol for 20 min; slices
were then blocked in blocking solution (4% FBS and 1% BSA) 1 h at
37 C in a humidiﬁed chamber. Primary antibody used was rabbit
polyclonal anti-14-3-3f (1:200; Santa Cruz Biotechnology). Anti-body binding was visualized by a biotin-extravidin-peroxidase kit
(Sigma–Aldrich) using as substrate 3-amino-9-ethyl carbaxole,
AEC, (Sigma). Slideswere counterstainedwithhematoxylin (Merck).
2.5. Western blot analysis
Frozen tissue and cultured cellswerehomogeneized in lysis buffer
containing 20mM MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM sodium
ﬂuoride, 60 mMb-glycerophosphate, 20 mMsodiumpyrophosphate,
1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl ﬂuo-
ride, 1% Triton X-100 and one time protease inhibitors mixture (GE
Healthcare). Total protein concentration was determined using the
Bio-Rad assay kit (Bio-Rad). 50 lg of protein were applied and sepa-
rated by SDS–PAGE and transferred to a nitrocellulose Hybond-C
membrane (GE Healthcare), using a wet system. The membrane
was blocked 1 h at room temperature in blocking buffer, 5% non-fat
dry milk in phosphate-buffered saline Tween-20 (PBST), and then
incubated overnight a 4 C with primary antibodies diluted in block-
ing buffer, namely rabbit polyclonal 14-3-3f (1:1000; Santa Cruz Bio-
technology), rabbit polyclonal LC3 (1:1000; Cell Signaling), mouse
monoclonal anti-polyubiquitinated conjugates (1:1000; Enzo Life
Sciences), mouse a-tubulin (1:10000; Sigma), mouse monoclonal
anti-b-actin (1:5000; Sigma) and rabbit polyclonal antibodies for
14-3-3c (1:2000) and 14-3-3g (1:1000) (kindly provided by Dr. Ala-
stair Aitken, Edinburgh). Membranes were then incubated with
horseradish peroxidase (HRP)-labeled secondary antibodies, namely
anti-rabbit IgG-HRP (1:10000) or anti-mouse IgG-HRP (1:5000), both
from theBinding Site, during 1 h at room temperature. Theblotswere
developed using the ECL PlusTM Western blotting reagents (GE
Healthcare) and exposed toHyperﬁlmECL (GEHealthcare). Quantita-
tive analyses were performed using the ImageJ software. Results are
shown as the ratio of 14-3-3f and b-actin or a-tubulin signals.
2.6. Reverse transcriptase–polymerase chain reaction
Total RNA was isolated using Trizol reagent (Invitrogen). First-
strand cDNA was synthesized using the Superscript II kit (Invitro-
gen). PCR was performed with the following oligonucleotides to
mouse 14-3-3f: 50-TGAGCAGGGAGCTGAGCTGTC-30 and 50-GTTGC
GAAGCATTGGGGATCAAGA-30; for mouse b-actin: 50-CTGTTTGATG
TCACGCACGAT-30 and 50-GTGGGCCGCTCTAGGCACCAA-30. For rat
ampliﬁcation of 14-3-3f in AF5 cells, primers used were: 50-CGCCA
CCCACTCCGGACACAGAATA-30, 50-TCTGGCTGCGAAGCATTGGGGA-
30 and for rat b-actin: 50-CCACCATCACACCCTGGTGCC-30and 50-GT
CGAGTCCGCGTCCACCC-30.
Ethidium bromide-stained gels were scanned using GENE
FLASH syngene bio imaging equipment. The results were analyzed
using the ImageJ software.
2.7. Statistical analysis
Quantitative data are presented as mean ± S.E.M. Statistical
analysis was carried out using Graphpad Prism 5 software. Differ-
ences among groups were analyzed by one-way ANOVA (followed
by Bonferroni’s Multiple Comparison Test), comparisons between
two groups were made by Student’s t test. P values of lower than
0.05 were considered signiﬁcant.3. Results
3.1. Hippocampus of TTR/ animals have decreased 14-3-3f protein
levels
To unravel differences between TTR/ and TTR+/+ mice hippo-
campus homogenates from 5 month old mice were analyzed by
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differences was identiﬁed as the 14-3-3f isoform, which clearly
had lower levels in the hippocampus of TTR/ mice when com-
pared with wild type littermates (Supplement 1). To further con-
ﬁrm the results obtained in 2D, Western blots for 14-3-3f of
hippocampus of TTR+/+, TTR heterozygous (+/) and TTR/ mice
of the same age were performed. The 14-3-3f levels in TTR/ mice
were signiﬁcantly decreased when compared with TTR+/+ animals;
in turn, levels in heterozygote mice were lower when compared
with TTR+/+ animals and signiﬁcantly increased as compared to
TTR/ mice, presenting intermediate levels between TTR+/+ and
TTR/ animals (Fig. 1A). Analysis of other brain areas such as cer-
ebellum, hypothalamus, choroid plexus, did not reveal any effect of
the absence of TTR on 14-3-3f levels, showing that this effect is
speciﬁc for the hippocampus (Supplement 2).Fig. 1. Absence of TTR correlates with decreased levels of 14-3-3f in hippocampus in an
in hippocampus samples at 5 months from TTR+/+ (n = 4), TTR+/ (n = 5) and TTR/ (n = 5
and TTR+/+ animals. (B) Western blot analysis and quantiﬁcation of 14-3-3f levels in TTR/
blots). In older animals, the levels of 14-3-3f are similar between TTR+/+ (n = 4) and TTR/
the hippocampus (CA1 region) of TTR/ mice present lower levels when compared with
a biotin-extravidin-peroxidase kit using AEC as substrate. Slides were counterstained w3.2. The effect of TTR in 14-3-3f protein levels is age dependent in a
transcriptional independent manner
It has been described that TTR CSF levels are decreased with age
[25,28]. To evaluate if the effect of TTR in 14-3-3f levels is age
dependent, immunohistochemistry of brain andWestern blot anal-
ysis of hippocampus was performed in TTR+/+ and TTR/ mice at 3,
6 and above 12 months of age.
Western blot analysis of hippocampus showed a 50% reduction
in 14-3-3f protein levels in TTR/ mice when compared with
TTR+/+ animals, both at 3 and 6 months of age; no difference was
observed between the two genotypes in older mice (Fig. 1B).
This result was corroborated by immunohistochemistry; in fact
at 3 months TTR/ mice presented clear decreased levels of
14-3-3f in the hippocampus when compared with TTR+/+ mice.age dependent manner. (A) Western blot analysis and quantitative charts of 14-3-3f
) mice showing that 14-3-3f levels were lower in TTR/ when compared to TTR+/
 hippocampus when compared to TTR+/+ mice at 3 and 6 months (upper and middle
 (n = 3) animals (lower blots). (C) Immunohistochemistry to 14-3-3f at 3 months in
TTR+/+ mice. No difference was observed in older animals. 14-3-3fwas visualized by
ith hematoxylin. Scale bar = 20 lm. Error bars represent S.E.M. ⁄P < 0.05; ⁄⁄P < 0.01.
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ished in animals older than 12 months (Fig. 1C).
Despite the fact that 14-3-3 isoforms are highly conserved, each
isoform has different and speciﬁc functions. To verify the effect of
TTR on c and g isoforms, Western blot of hippocampus of
3 months animals were performed. No differences were observed
in these 14-3-3 isoforms (Supplement 3).
In order to assess if the inﬂuence of TTR on 14-3-3f levels occurs
at the transcriptional level, semi-quantitative RT-PCR analysis for
14-3-3f was performed for hippocampus of TTR+/+ and TTR/ ani-
mals at 3, 6 and 12 months, respectively. No differences in 14-3-3f
transcription were observed, between the two genotypes at the
analyzed ages (data not shown).
3.3. 14-3-3f protein levels are down-regulated in hippocampal
neurons in the absence of serum TTR
To evaluate the effect of TTR on 14-3-3f levels in cultured neu-
rons, hippocampal neurons from TTR/ embryonic mice were iso-
lated and exposed to sera collected either from TTR+/+ and TTR/
mice, during 75 min at 37 C. Western blot analysis revealed that
14-3-3f levels decrease in cells treated with TTR/ serum when
compared with TTR+/+ serum (Fig. 2A). No signiﬁcant differences
were observed in 14-3-3f transcription in the presence/absence
of TTR, as the mRNA levels of 14-3-3f did not change signiﬁcantly
(Fig. 2B).
3.4. TTR inﬂuences 14-3-3f degradation
To better understand the mechanism by which absence of TTR
decreases 14-3-3f levels, AF5 cells were used as a cell model. These
cells do not synthetize TTR (data not shown) and have been used
addressing the behavior of 14-3-3f to excitotoxicity in neuropro-
tection studies [29].
AF5 cells were cultured during 18 h with TTR+/+ or TTR/ serum
to replace FBS. Western blot analysis displayed highly decreased
levels of 14-3-3f when cells grew in TTR/ serum as compared
to cells exposed to TTR+/+ serum (Fig. 3A). As observed in the above
described studies with cultured hippocampal neurons, no differ-
ences were found in 14-3-3f at the transcriptional level in cellsFig. 2. 14-3-3f levels were signiﬁcantly lower in hippocampal neurons exposed to
TTR/ serum when compared with neurons exposed to TTR+/+ serum. (A)
Representative image of Western blot in neurons cultured in TTR/ serum when
compared with neurons in the presence of TTR+/+ serum and respective quantiﬁ-
cation (lower blots). (B) Semi-quantitative RT-PCR analysis of 14-3-3f expression
under the same conditions. Data represents the means ± S.E.M. of three indepen-
dent experiments. Error bars represent S.E.M. ⁄P < 0.05; ⁄⁄P < 0.01.grown under the two different conditions (data not shown). This
indicates that the effect of TTR on 14-3-3f protein levels occurs
post-transcriptionaly.
We reasoned that the decrease of 14-3-3f protein levels in the
absence of TTR might be due to active degradation of the protein.
The majority of intracellular proteins are degraded by proteasome
or lysosome pathways [30]. To assess if TTR is involved in the deg-
radation process of 14-3-3f by the proteasome, AF5 cells were ex-
posed to 10 lM of the proteasome inhibitor MG132. The inhibition
of the proteasome did not invert the effect triggered by TTR/ ser-
um, indicating that the proteasome is not involved in the 14-3-3f
differential degradation (Fig. 3A). To conﬁrm the effectiveness of
MG132, a Western blot to polyubiquitinated proteins were per-
formed in the presence of MG132, and increased polyubiquitinated
proteins was observed (Fig. 3B).
To evaluate if 14-3-3f was differentially degraded by the lyso-
some, AF5 cells were exposed to 100 lM of the lysosome inhibitor
chloroquine. Use of chloroquine in cells treated with TTR/ serum
did not induce any difference in 14-3-3f levels when compared
with the same situation without the inhibitor, as shown in
Fig. 3C. However inhibition of lysosome abolishes the differential
effect of TTR on 14-3-3f levels. These results suggest that TTR con-
trols 14-3-3f degradation by the lysosome.
Autophagy, also referred as programmed cell death type II, is
characterized by the presence of autophagosomes that fuse with
lysosomes for degradation of sequestered material. Autophagy
marker Light Chain 3 (LC3), involved in autophagosome formation,
undergoes post-translational modiﬁcation in autophagy. LC3 exists
in two cellular forms, LC3-I (18 kDa) and LC3-II (16 kDa). During
autophagy LC3-I is converted in LC3-II, being the amount of LC3-
II a marker of this process. 14-3-3f is a negative regulator of auto-
phagic activity [31,32]. When AF5 cells were exposed to TTR/
serum, the levels of LC3-II were signiﬁcantly increased when com-
pared with cells grown in the presence of serum TTR (Fig. 3D, left
panel). The effectiveness of chloroquine was proved by increase in
LC3-II levels when compared with control situation; thus, the ef-
fect of TTR in preventing autophagy is not observed when chloro-
quine is used (Fig. 3D, right panel).
The lower 14-3-3f levels that are associated with the absence of
TTR induce increased autophagy.4. Discussion
The present study demonstrates for the ﬁrst time that TTR reg-
ulates 14-3-3f protein levels. Immunohistochemistry and Western
blot studies showed reduced levels of 14-3-3f in the hippocampus
of TTR null mice as compared to TTR wild type animals. This ﬁnd-
ing occurs in young/adult animals (3 and 6 months, respectively)
and is not observed in older animals (>12 months). 14-3-3 proteins
have been described as decreased with aging. 14-3-3 gamma and
epsilon had decreased levels in adult brain when compared with
neonatal brain [33]. 14-3-3h, 14-3-3c, and 14-3-3f expression lev-
els decreased with aging [34]. It is well known that TTR levels in
CSF decrease with age; thus 18-month-old mice present a 30% de-
crease of TTR levels in CSF when compared with 5 months animals
[25]. So the decrease of TTR in the CSF of old animals could be
responsible for the abolishment of differences on 14-3-3f levels
between TTR wild type and TTR null mice. Several important
neurobiological processes are associated with advancing age such
as increased oxidative stress, decrease metabolism, protein synthe-
sis and trafﬁcking. Cognitive decline is strongly associated with de-
crease expression in synaptic activity- dependent proteins, which
14-3-3h is included [35].
TTR in CSF is mainly derived from synthesis and secretion by
the choroid plexus. Synthesis of TTR by the hippocampus has not
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campal and cortical neurons can synthetize TTR, other authors sug-
gest that this synthesis might be due to choroid plexus
contamination in the experimental procedures [36]. To overcome
this issue and avoid misleading conclusions, hippocampal neurons
from TTR null mice and AF5 cell lines which do not synthesize TTR
were used. This way, a possible contribution of endogenous TTR
was ruled out. Instead, exogenous TTR contributed to regulate dis-
posal of 14-3-3f at the lysosomal compartment. Internalization of
TTR by neurons is a well documented process, not only in primary
cultures [9] but also in cell lines of neuronal origin [37], as well as
uptake by a variety of other cell types [38].
In neurons, 14-3-3 proteins exist in cytoplasm, in mitochondria,
microsomes and also in the nucleus [39,40]. Decreased 14-3-3c
and f isoforms were detected in rats, in microsomes of hippocam-
pus, after damaging seizures. As the levels of these proteins do not
increase in other cellular fractions, proteolysis has been theFig. 3. TTR inﬂuences 14-3-3f degradation. AF5 cells treated with TTR+/+ or TTR/ seru
MG132. Data represents the means ± S.E.M. of six independent experiments. (B) Western
Western blot analysis of 14-3-3f in the presence or absence of chloroquine. (D) TTR inﬂue
LC3-II/b-actin ratio (lower panel). Data represents the means ± S.E.M. of three independmechanism proposed to explain this reduction. In this type of
evoked seizures, it is known that 14-3-3 is proteolyzed by caspase
3 during apoptosis [39,41]. When cortical neurons cultures are ex-
posed to necrotic agents, 14-3-3f is released to the medium cul-
ture, being considered a surrogate marker of acute brain damage
[42]. Although TTR null mice had decreased levels of 14-3-3f, ab-
sence of TTR did not induce cellular death in hippocampal slices
cultures, when compared with wild type animals [43]. The de-
creased levels of 14-3-3f found in the absence or lower TTR levels
(as in the case of heterozygote animals) are highly unlikely related
to cellular death.
14-3-3 proteins interact with more than 400 molecules and
their action is based mostly on altering the conformation of the tar-
gets, physical occlusion of sequence-speciﬁc or structural features
and scaffolding [44]. The interaction of 14-3-3 proteins with their
binding partners occurs, mostly, through phospho-serine/phos-
pho-threonine residues. The main binding motifs are RSXpSXPm during 18 h. (A) Western blot analysis of 14-3-3f in the presence or absence of
blot analysis of polyubiquitinated proteins in the presence or absence of MG132. (C)
nces autophagy. LC3-II Western blot analysis (upper panel) and quantiﬁcation of the
ent experiments. Error bars represent S.E.M. ⁄P < 0.05; ⁄⁄P < 0.01.
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matic or aliphatic amino acid and X is any amino acid [45]. The
interaction of 14-3-3 proteins can also occur with the C-terminal
of the protein through (pS/pT)X1-2-COOH sequence [46]. It is
important to note that not all interactions are phosphorylation
dependent. Analysis of TTR sequence did not reveal any of the
binding motifs above described (data not shown), which is sugges-
tive that the effect of TTR on 14-3-3f levels might not necessarily
encompass a direct structural interaction. Alternatively, TTR might
bind another molecule, either at the membrane, in the endocytic or
lysosomal compartment (where TTR is degraded) resulting in acti-
vation of an intermediate molecule that interacts/stabilizes 14-3-
3f. The physical interaction of TTR with the most abundant lyso-
somal protein, LAMP-1, was previously described [47]. Although
that study was performed with LAMP-1 in circulation, it is reason-
able to speculate that this interaction could also occur within cells
to regulate lysosomal activity, in particular of 14-3-3f, preventing
degradation. In fact, inhibition of lysosome abolished the effect of
TTR in this organelle. These are possibilities that need to be dis-
cerned and the subject of future studies.
The speciﬁcity of TTR to regulate 14-3-3f but not other isoforms
as well as the effect only in hippocampus also merits future
investigation.
At this point we attribute TTR effect on autophagy to regulation
of 14-3-3f levels in view of the well known negative regulation of
autophagy by this isoform, through the bind to hVps34 (the class III
phosphatidylinositol-3-kinase) [31,32]. TTR regulation of autoph-
agy becomes a pivotal subject of study; retinoic acid, a molecule
transported by TTR, promotes autophagosome maturation [48],
through the cation-independent mannose-6-phosphate receptor
[49].
In physiological terms, decreased 14-3-3f levels can impact in
learning and memory. In Drosophila, the 14-3-3zeta gene named
Leonardo, is highly expressed in adult mushroom bodies, centers
of insect learning and memory, and mutant ﬂies have a deﬁcit in
memory and learning [22,23]. 14-3-3f-deﬁcient mice present the
same type of deﬁcits observed in the Drosophila studies, as well
as hyperactivity and disrupted sensorimotor gating. This mice
model also exhibits abnormal neuronal migration and glutamater-
gic synapse formation, as well functional disrupted mossy ﬁber cir-
cuit [24]. Young/adults TTR null mice display spatial reference
memory impairment when compared with age matched controls
[25]. The difference disappears in older animals. Correlating the
phenotype of young/adult TTR null mice with the reduced capacity
observed in 14-3-3f-deﬁcient mice to learn and memorize, it is
tempting to speculate that memory impairment observed in adult
TTR null mice as compared to wild-type age matched controls, can
relate to reduced levels of 14-3-3f in the hippocampus. Future bio-
chemical and genetic studies should address this hypothesis.
In conclusion, our study showed that the absence of TTR de-
creases 14-3-3f protein levels in the hippocampus. The reduced
levels of 14-3-3f found in vitro and in vivo, are attributable to in-
creased degradation in the lysosomal compartment. Increase in
autophagy is observed in the absence of TTR, probably by the re-
duced levels of 14-3-3f.
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